

# Hongge Liang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1894560/publications.pdf>

Version: 2024-02-01

17  
papers

301  
citations

1307594

7  
h-index

940533

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 879554.	2.8	0
2	Prognostic impact of maximum standardized uptake value on 18 Fâ€FDG PET / CT imaging of the primary lung lesion on survival in advanced nonâ€small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 845-853.	1.9	7
3	A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 727662.	2.8	3
4	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	4.8	11
5	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. <i>Clinical Respiratory Journal</i> , 2020, 14, 1131-1136.	1.6	6
6	Patterns of response in metastatic NSCLC during PDâ€1 or PDâ€1.1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. <i>Thoracic Cancer</i> , 2020, 11, 1068-1075.	1.9	15
7	&lt;p&gt;MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2491-2510.	2.0	65
8	&lt;p&gt;Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719.	1.9	45
9	<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8191-8200.	1.9	4
10	Realâ€world data on EGFR/ALK gene status and firstâ€line targeted therapy rate in newly diagnosed advanced nonâ€small cell lung cancer patients in Northern China: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 1521-1532.	1.9	18
11	Clinical features and outcomes of <i>ALK</i> rearranged nonâ€small cell lung cancer with primary resistance to crizotinib. <i>Thoracic Cancer</i> , 2019, 10, 1213-1219.	1.9	5
12	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , 2019, 14, 325-333.	3.6	9
13	Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 481-488.	2.2	5
14	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20513-e20513.	1.6	0
15	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. <i>Future Oncology</i> , 2018, 14, 665-674.	2.4	49
16	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6189-6196.	2.0	47
17	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. <i>Journal of Thoracic Disease</i> , 2018, 10, 3965-3972.	1.4	9